Taiko Pharmaceutical Co.,Ltd.
Stock Price Chart
2026/08/25 UpdatedPrice Trend
2026/08/25 UpdatedPrice & Trading Details
2026/08/25 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥3 | -90.6% |
| 2020 | ¥35 | +199.9% |
| 2019 | ¥12 | 0.0% |
| 2018 | ¥12 | +75.0% |
| 2017 | ¥7 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥5,040M | ¥6,120M | ¥6,292M | ¥6,397M |
| Gross Profit | ¥1,078M | ¥2,577M | ¥3,666M | ¥3,481M |
| Operating Income | -¥3,079M | -¥1,006M | ¥630M | ¥459M |
| Pretax Income | -¥4,859M | -¥3,555M | ¥573M | ¥963M |
| Net Income | -¥4,895M | -¥3,611M | ¥898M | ¥923M |
| EPS | -¥112.26 | -¥76.25 | ¥17.90 | ¥18.38 |
| Operating Margin | -61.09% | -16.44% | 10.01% | 7.18% |
| Balance Sheet | ||||
| Total Assets | ¥15,046M | ¥13,220M | ¥12,914M | ¥12,270M |
| Total Equity | ¥8,043M | ¥6,738M | ¥7,963M | ¥8,518M |
| Total Liabilities | ¥7,003M | ¥6,482M | ¥4,951M | ¥3,752M |
| Cash | ¥3,105M | ¥5,484M | ¥4,532M | ¥4,256M |
| Interest-bearing Debt | ¥3,809M | ¥3,254M | ¥2,211M | ¥970M |
| Equity Ratio | 53.46% | 50.97% | 61.66% | 69.42% |
| D/E Ratio | 0.47 | 0.48 | 0.28 | 0.11 |
| Cash Flow | ||||
| Operating CF | -¥1,994M | -¥307M | ¥362M | ¥814M |
| Investing CF | ¥190M | ¥1,166M | -¥5M | ¥142M |
| Financing CF | -¥997M | ¥1,539M | -¥1,181M | -¥1,227M |
| Free CF | -¥2,078M | -¥421M | ¥175M | ¥510M |
| Efficiency | ||||
| ROE | -60.86% | -53.59% | 11.28% | 10.84% |
| ROA | -32.53% | -27.31% | 6.95% | 7.52% |
Latest IR Information
-
Notice regarding the application for market category change to the Tokyo Stock Exchange Standard Market
Although sales and profit figures are unknown, the company has resolved to apply for a market category change to the Standard Market. The current issue of market capitalization relative to tradable shares continuing to fail to meet Prime Market criteria...
Read more -
[Taiko Pharmaceutical] 2026 Q2 Consolidated Financial Results Summary｜Sales and Profit Trends
Discloses key metrics such as net sales, operating income, and ordinary income. For the FY2026 interim period, multiple sections show growth or YoY changes in net sales. Segments compare sales and profits, with trends in costs and SG&A, and factors...
Read more
Latest News (5 items)
Company Information
About
Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines and quasi drugs in Japan and internationally. The company provides OTC medicines under the SEIROGAN, SEIROGAN TOI A and SEIROGAN Quick C, PISHUT OD Tablet brand names; and quasi-drugs under the RAPPA INTESTINAL REGULATOR BF brand names. It offers sanitation control products under the Cleverin PR, Cleverin Pro Stick, and Cleverin Pro name. In addition, the company manufactures and sells wood vinegar-based products. It exports its products. The company was incorporated in 1946 and is headquartered in Osaka, Japan.
